Sells it“Gives providers, payers, and health technology companies frontier models with domain intelligence across clinical reasoning, medical coding, and long-horizon agentic operations, as well as tools designed to support HIPAA compliance for medical and operational workflows.”
Latest 424B4final IPO prospectusMixedControlled company ·
Sells Claude AI models and coding tools; $81.3B offering funds compute expansion
Sells it, part of Patient And Digital Solutions“Our Ottr software consists of two unique offerings, Ottr Organ and Ottr Cellular, which provide comprehensive solutions for transplant patient management and enable integration with electronic medical records, or EMR, systems, including Cerner and Epic, providing patient surveillance management tools and outcomes data to transplant centers.”
Latest 10-KFY2025Mixed ·
Pharmacy and Ottr expansion drive growth beyond testing, while reimbursement and collection adjustments limit revenue per test.
Revenue$379.8MYoY +13.8%
Net income−$21.4Mvs $52.5M year ago
Latest 10-QQ3 FY2026Positive ·
Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.
Revenue$139.4MYoY +39.3%
Net income$19.3Mvs $1.7M year ago
Latest 8-KPositiveEarningsGuidance raised ·
Testing Services growth, including NavDx oncology, fuels higher FY2026 revenue guidance of $520M–$530M.
Latest 8-KPositiveDeal completed ·
Sold Lab Products to Eurobio for $171.7M and acquired Naveris for $161.8M upfront, adding NavDx specialty oncology testing.
Latest 8-KExecutive payShareholder vote ·
Stockholders approved adding 1.6M shares to the 2024 Equity Incentive Plan reserve.
Sells it“My Intuitive+ is a digital subscription package available with the da Vinci 5 platform.”
Latest 10-KFY2025 ·
Intuitive Surgical delivered broad-based FY2025 growth as rising procedure volumes expanded recurring revenue and da Vinci 5 accelerated system placements. Revenue increased 21% and operating income increased 25%, despite lower gross margins from tariffs, new-system costs, manufacturing expansion, and service repairs. The investment case rests on converting a larger installed base into sustained…
da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth
Latest 8-KGovernance change ·
Bylaws tighten shareholder nomination and proxy rules; non-director-election actions shift to majority of votes cast, excluding abstentions and broker non-votes.
Latest 8-KBuybackExecutive payShareholder vote ·
Board expands buyback authorization to $5.0B; stockholders extend the incentive plan and increase its share reserve.
Latest 8-KPositiveDeal completed ·
Acquisition of da Vinci and Ion distributors expands direct operations in Italy, Spain and Portugal.
Sells it“Oracle Health applications, which are designed to enable medical professionals to deliver better healthcare to individual patients and communities.”
Sells it“Oura App, available on iOS and Android in 21 languages, is the primary interface through which members access and engage with their health data.”
Latest S-1/Aamended IPO prospectusPositiveLegal / investigationProceeds to insiders or debt ·
Smart rings and health subscriptions; offering mainly benefits selling holders, while company proceeds largely cover equity-award taxes